These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

779 related items for PubMed ID: 8636300

  • 21. Suppression of spermatogenesis in man induced by Nal-Glu gonadotropin releasing hormone antagonist and testosterone enanthate (TE) is maintained by TE alone.
    Swerdloff RS, Bagatell CJ, Wang C, Anawalt BD, Berman N, Steiner B, Bremner WJ.
    J Clin Endocrinol Metab; 1998 Oct; 83(10):3527-33. PubMed ID: 9768659
    [Abstract] [Full Text] [Related]

  • 22. Inhibition of spermatogenesis in men using various combinations of oral progestagens and percutaneous or oral androgens.
    Guerin JF, Rollet J.
    Int J Androl; 1988 Jun; 11(3):187-99. PubMed ID: 2970439
    [Abstract] [Full Text] [Related]

  • 23. Depot gonadotropin-releasing hormone agonist blunts the androgen-induced suppression of spermatogenesis in a clinical trial of male contraception.
    Behre HM, Nashan D, Hubert W, Nieschlag E.
    J Clin Endocrinol Metab; 1992 Jan; 74(1):84-90. PubMed ID: 1727833
    [Abstract] [Full Text] [Related]

  • 24. Gonadotropin-releasing hormone antagonist plus testosterone: a potential male contraceptive.
    Bremner WJ, Bagatell CJ, Steiner RA.
    J Clin Endocrinol Metab; 1991 Sep; 73(3):465-9. PubMed ID: 1874925
    [Abstract] [Full Text] [Related]

  • 25. Clinical evaluation of long-term treatment with levo-norgestrel and testosterone enanthate in normal men.
    Foegh M, Nicol K, Petersen IB, Schou G.
    Contraception; 1980 Jun; 21(6):631-40. PubMed ID: 6775869
    [Abstract] [Full Text] [Related]

  • 26. Intramuscular testosterone undecanoate with or without oral levonorgestrel: a randomized placebo-controlled feasibility study for male contraception.
    Kamischke A, Plöger D, Venherm S, von Eckardstein S, von Eckardstein A, Nieschlag E.
    Clin Endocrinol (Oxf); 2000 Jul; 53(1):43-52. PubMed ID: 10931079
    [Abstract] [Full Text] [Related]

  • 27. Combined administration of a gonadotropin-releasing hormone antagonist and testosterone in men induces reversible azoospermia without loss of libido.
    Pavlou SN, Brewer K, Farley MG, Lindner J, Bastias MC, Rogers BJ, Swift LL, Rivier JE, Vale WW, Conn PM.
    J Clin Endocrinol Metab; 1991 Dec; 73(6):1360-9. PubMed ID: 1955518
    [Abstract] [Full Text] [Related]

  • 28. A combined regimen of cyproterone acetate and testosterone enanthate as a potentially highly effective male contraceptive.
    Meriggiola MC, Bremner WJ, Paulsen CA, Valdiserri A, Incorvaia L, Motta R, Pavani A, Capelli M, Flamigni C.
    J Clin Endocrinol Metab; 1996 Aug; 81(8):3018-23. PubMed ID: 8768868
    [Abstract] [Full Text] [Related]

  • 29. Reversible inhibition of sperm production and gonadotrophin secretion in men following combined oral medroxyprogesterone acetate and percutaneous testosterone treatment.
    Soufir JC, Jouannet P, Marson J, Soumah A.
    Acta Endocrinol (Copenh); 1983 Apr; 102(4):625-32. PubMed ID: 6221496
    [Abstract] [Full Text] [Related]

  • 30. Hormonal contraception in Chinese men: variations in suppression of spermatogenesis with injectable testosterone undecanoate and levonorgestrel implants.
    Liu ST, Gui YL, Lin CH, He CH.
    Asian J Androl; 2004 Mar; 6(1):41-6. PubMed ID: 15064833
    [Abstract] [Full Text] [Related]

  • 31. Suppression of spermatogenesis by testosterone enanthate in Thai men.
    Aribarg A, Sukcharoen N, Chanprasit Y, Ngeamvijawat J, Kriangsinyos R.
    J Med Assoc Thai; 1996 Oct; 79(10):624-9. PubMed ID: 8996996
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Intramuscular testosterone undecanoate and norethisterone enanthate in a clinical trial for male contraception.
    Kamischke A, Venherm S, Plöger D, von Eckardstein S, Nieschlag E.
    J Clin Endocrinol Metab; 2001 Jan; 86(1):303-9. PubMed ID: 11232016
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. An effective hormonal male contraceptive using testosterone undecanoate with oral or injectable norethisterone preparations.
    Kamischke A, Heuermann T, Krüger K, von Eckardstein S, Schellschmidt I, Rübig A, Nieschlag E.
    J Clin Endocrinol Metab; 2002 Feb; 87(2):530-9. PubMed ID: 11836281
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Suppression of spermatogenesis by etonogestrel implants with depot testosterone: potential for long-acting male contraception.
    Anderson RA, Kinniburgh D, Baird DT.
    J Clin Endocrinol Metab; 2002 Aug; 87(8):3640-9. PubMed ID: 12161488
    [Abstract] [Full Text] [Related]

  • 39. Effects of testosterone and levonorgestrel combined with a 5alpha-reductase inhibitor or gonadotropin-releasing hormone antagonist on spermatogenesis and intratesticular steroid levels in normal men.
    Matthiesson KL, Stanton PG, O'Donnell L, Meachem SJ, Amory JK, Berger R, Bremner WJ, McLachlan RI.
    J Clin Endocrinol Metab; 2005 Oct; 90(10):5647-55. PubMed ID: 16030154
    [Abstract] [Full Text] [Related]

  • 40. Spermatogenesis in men treated with injections of medroxyprogesterone acetate combined with testosterone enanthate.
    Frick J, Danner C, Kunit G, Joos H, Köhle R.
    Int J Androl; 1982 Jun; 5(3):246-52. PubMed ID: 7118265
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 39.